Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04550442
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2020-09-09
Brief Title:
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Therapy-Related Myelodysplastic Syndrome |
| Recurrent Chronic Myelomonocytic Leukemia |
| Recurrent Myelodysplastic Syndrome |
| Refractory Chronic Myelomonocytic Leukemia |
| Refractory Myelodysplastic Syndrome |
Keywords: